Fed signals more rate cuts to come, President Trump and tech leaders meet in the UK

Group 1: Federal Reserve and Economic Indicators - The Federal Reserve cut interest rates by 25 basis points, marking the first cut of the year, with expectations for two more cuts later in the year [5][14][51] - The Fed's decision reflects concerns about a weakening labor market and rising inflation pressures, with a focus on balancing these factors [12][13][20] - Initial jobless claims are forecasted to fall to 240,000, indicating a slowdown in layoffs [8][52] Group 2: U.S.-China Trade Relations - China has ended its antitrust probe into Google, which began in February, as trade talks between the U.S. and China intensify [2][3] - The investigation was centered on Google's Android operating system, which is widely used by Chinese phone manufacturers [3] - Nvidia's business in China is under scrutiny, with Chinese authorities blocking sales of Nvidia processors to major Chinese tech companies [36] Group 3: Meta's New Product Launch - Meta has launched new AI-powered smart glasses, the Ray-Ban display, retailing for $799, which will ship in the U.S. on September 30 [22][24] - The glasses feature a neural band that allows users to control them through subtle finger and wrist movements [22][25] Group 4: Apple iPhone Launch - Apple has introduced a new lineup of iPhones, including the iPhone Air, iPhone 17, and iPhone 17 Pro, with significant design changes after years of stagnation [26][34] - The iPhone Air is notably thin at 5.6 mm and features Apple's new A19 processor, while the Pro models offer enhanced camera capabilities [28][31] - Pricing for the new iPhones starts at $799 for the standard model and goes up to $1,199 for the Pro Max [31][32] Group 5: Market Reactions and Stock Movements - Nvidia's shares are experiencing volatility due to trade negotiations, but analysts remain optimistic about its long-term growth [36] - Lyft's stock is fluctuating following a partnership with Alphabet's autonomous vehicle unit, which has raised investor optimism [39] - Nova Nordisk's shares rose nearly 7% after positive results from a phase 3 trial for its new obesity drug, indicating potential recovery for the company [41]